INmune Bio (NASDAQ:INMB) Trading Up 2.5%

INmune Bio, Inc. (NASDAQ:INMBGet Rating) shares were up 2.5% on Friday . The stock traded as high as $7.78 and last traded at $7.36. Approximately 33,300 shares traded hands during mid-day trading, a decline of 38% from the average daily volume of 53,659 shares. The stock had previously closed at $7.18.

INmune Bio Price Performance

The company’s 50-day moving average price is $7.35 and its two-hundred day moving average price is $7.69. The company has a market cap of $132.08 million, a P/E ratio of -4.94 and a beta of 1.94. The company has a current ratio of 5.53, a quick ratio of 5.53 and a debt-to-equity ratio of 0.13.

INmune Bio (NASDAQ:INMBGet Rating) last released its earnings results on Thursday, March 2nd. The company reported ($0.32) earnings per share for the quarter. The company had revenue of $0.10 million during the quarter. INmune Bio had a negative return on equity of 43.26% and a negative net margin of 10,816.06%.

Institutional Investors Weigh In On INmune Bio

Institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC bought a new stake in shares of INmune Bio during the 3rd quarter valued at about $25,000. Bank of America Corp DE grew its position in shares of INmune Bio by 152.1% during the 1st quarter. Bank of America Corp DE now owns 4,717 shares of the company’s stock valued at $30,000 after buying an additional 2,846 shares during the last quarter. Advisor Group Holdings Inc. grew its position in shares of INmune Bio by 52.9% during the 4th quarter. Advisor Group Holdings Inc. now owns 9,250 shares of the company’s stock valued at $59,000 after buying an additional 3,200 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of INmune Bio during the 1st quarter valued at about $84,000. Finally, Financial Advocates Investment Management bought a new stake in shares of INmune Bio during the 4th quarter valued at about $87,000. Institutional investors own 10.66% of the company’s stock.

About INmune Bio

(Get Rating)

INmune Bio, Inc Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Featured Articles

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.